



Figure 1**Figure 2**

Figure 3




Figure 4




Figure 5




Figure 6




Figure 7.




Figure 8.




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16






Figure 17**Figure 18**

Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26






Figure 27**Figure 28**

Figure 29




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39




Figure 40




Figure 41




Figure 42




Figure 43




Figure 44




Figure 45




Figure 46




Figure 47




Figure 48





Figure 49






FIG. 50




FIG. 51




FIG. 52




FIG. 53




FIG. 54




FIG. 55

Figure 56




Figure 57(A) Cytotoxicity of anti-CD56(huN901) antibody-maytansinoid conjugates




Figure 57(B) Cytotoxicity of anti-CD56(huN901) antibody-maytansinoid conjugates






Figure 57(C) Cytotoxicity of anti-CD56(huN901) antibody-maytansinoid conjugates




CYTOTOXICITY: huC242-SULFONATE LINKER-DM4, (5.4 D/A)' VS.
COLO 205 & MOLT-4 CELLS




COLO 205 CELLS	3.3e-11 M
MOLT-4 CELLS	> 6.0e-9 M

CYTOTOXICITY: huC242-SULFONATE LINKER-DM4, (6.3 D/A)' VS.
COLO 205 & MOLT-4 CELLS



COLO 205 CELLS	2.9e-11 M
MOLT-4 CELLS	> 6.0e-9 M

CYTOTOXICITY: huC242-SULFONATE LINKER-DM1, (5.4 D/A)' VS.
COLO 205 & MOLT-4 CELLS



COLO 205 CELLS	4.8e-11 M
MOLT-4 CELLS	2.3e-9 M

FIG. 58

MASS SPECTRAL ANALYSIS OF huC242-SULFONATE LINKER-DM1 CONJUGATE

DEGLYCOSYLATED C242-SPDB(SO₃)-DM1 (DAPENG)
ACL_010507_SEC_C242_SPDB_DM1_3 35 (7.805) Sb (25, 10.00); M1 [Ev-96612,It11]
(Gs, 1.700,2406:4000,2.00,L40,R40): Sb (25,10.00); Cm (31:49) 1: TOF MS ES+3.72e3




FIG. 59

Figure 60

Cytotoxicity of Anti-CanAg (huC242) -sulfonate linker-maytansinoid conjugates with increasing maytansinoids load (E:A) toward COLO205 cells.




Figure 61

Cytotoxicity of Anti-CanAg (huC242) -sulfonate linker-maytansinoid conjugates with increasing maytansinoids load (E:A) toward multi-drug resistant COLO205-MDR cells.




Figure 62

Cytotoxicity of Anti-CanAg (huC242) - maytansinoid conjugates with or without sulfonate linker toward multi-drug resistant COLO205-MDR cells.




Figure 63

Cytotoxicity of Anti-EpCAM (B38.1) - maytansinoid conjugates with or without sulfonate linker toward multi-drug resistant COLO205-MDR cells.




Figure 64

Cytotoxicity of Anti-EpCAM (B38.1)- maytansinoid conjugates with or without sulfonate linker toward multi-drug resistant HCT15 cells.




Figure 65

Cytotoxicity of Anti-EpCAM (B38.1) - maytansinoid conjugates with or without sulfonate linker toward multi-drug resistant COLO205-MDR cells.





Figure 66

In vivo anti-tumor activity of anti-EpCAM antibody-maytansinoid conjugates on COLO205 *mdr* xenografts (individual tumors).






FIG. 67




FIG. 68

Figure 69




Figure 70






Figure 71

FIGURES 72 (A) and (B). Plasma pharmacokinetics of huC242 Antibody-Sulfo-Mal- ^3H -labeled]-DM4 conjugates with 3.5 DM4/Ab or 6.4 DM4/Ab dosed at 12.9 mg/kg and 7.9 mg/kg (i.v.) respectively in CD-1 mice. A. Ab concentrations (measured by ELISA or by ^3H counts) versus time after administration. B. Maytansinoid (DM4)/Antibody (Ab) ratio versus time after administration.

FIGURE 72(A)



. FIGURE 72 (B)

